Univ.-Prof. Dr. Stephanie E. Combs

Klinikum rechts der Isar

Klinik und Poliklinik für Radio-Onkologie und Strahlentherapie

Ismaninger Str. 22

81675 München


Radiation Oncology and Imaging (ROI)

Molecularly Targeted Therapy (MTT)


Key research foci include the development of biomarkers for radiation response, prediction of normal tissue toxicity, as well as for the implementation of personalized radiation concepts. These treatment approaches include high-precision radiotherapy, novel dose and fractionation concepts, as well as the inclusion of innovative bio-imaging.
To date, the risk-benefit-ratio of modern treatments is excellent for most indications. However, indications such as pancreatic cancer of glioblastoma still remain the most devastating tumors with dismal prognosis, in spite of ongoing research activities in all fields. Here, we observe patient with long-term survival, as well as patients who literally progress during or shortly after treatment.
We aim at understanding the molecular properties underlying theses response patterns and use all information gained to personalize oncological treatment concepts.
In addition, development of novel radiation modalities is likely to help overcome radiation resistance. Therefore, we foster deep understanding of radiation effects of particle therapy, micro- and minibeam treatments, and promote all developments in this regard towards clinical implementation.
Members of the group are medical physicists, IT-specialists, radiation biologists as well as molecular biologist and clinician scientists. We strongly promote interdisciplinary collaboration with all neighboring disciplines. The group is well embedded into the structures of DKTK, national and international radiation oncology groups (ESTRO, ASTRO), as well as into research collaborations such as the Sonderforschungsbereich 1321 “Pancreatic Cancer” and the DFG Forschergruppe GRK 2274 “Advanced Medical Physics”.